How to Decide Between Class I, II, III Medical Device Registration in China
For foreign manufacturers, misclassification is one of the costliest mistakes in China market entry. An incorrect low-risk classification can lead to application rejection, while over-classifying adds unnecessary time and expense. Understanding the NMPA’s classification logic is therefore a strategic necessity.
The NMPA uses a risk-based system aligned with global standards. However, China’s rules differ from the U.S. FDA or EU MDR in several key areas. For example, China requires a separate clinical evaluation for many Class II devices, whereas the EU may accept literature-only evidence. These differences mean you cannot simply copy a foreign classification to China.
Below we examine the three classes, the decision factors, and provide a step-by-step guide. We also include a comparison table with real-world data from recent NMPA filings (2019–2024).
1. Understanding the NMPA Classification System
China’s medical device classification (医疗器械分类 yīliáo qìxiè fēnlèi) is defined in Regulation on the Supervision and Administration of Medical Devices (State Council Decree No. 739, 2021 revision). The system divides devices into three categories based on the degree of risk to the human body.
Class I (One / 一类 yī lèi) – Low risk. Examples: bandages, sterile cotton swabs, eyeglass frames. Registration is a simple filing (备案 bèi àn) with the city-level NMPA office. No clinical trial is required. Average approval time: 6–12 months from submission to certificate. Cost: USD 5,000–15,000 including agent fees.
Class II (Two / 二类 èr lèi) – Medium risk. Examples: blood pressure monitors, infusion pumps, diagnostic test strips. Registration requires provincial-level NMPA review. A clinical evaluation report (CER) may be needed, but not always a full clinical trial. Timeline: 12–24 months. Cost: USD 20,000–60,000.
Class III (Three / 三类 sān lèi) – High risk. Examples: coronary stents, implantable defibrillators, ventilators. Registration is handled by the national NMPA in Beijing. A full clinical trial in China is almost always mandatory. Timeline: 24–36 months (or longer for novel devices). Cost: USD 80,000–300,000.
Data from NMPA’s 2023 annual report shows that 29% of registered devices were Class I, 52% Class II, and 19% Class III. This reflects the dominance of medium-risk devices in China’s market.
2. Key Factors That Determine Classification
To decide the correct class for your device, consider the following five factors as defined by NMPA’s classification rules (医疗器械分类规则 Yīliáo Qìxiè Fēnlèi Guīzé).
- Degree of invasiveness – Non-invasive devices (e.g., ultrasound gel) are usually Class I. Devices that enter the body through natural orifices (e.g., catheters) are Class II or III depending on duration.
- Duration of contact – Temporary (< 60 minutes) vs. short-term (60 min – 30 days) vs. long-term (>30 days). Long-term contact typically pushes a device to a higher class.
- Body part affected – Contact with the cardiovascular system or central nervous system is always Class III. Skin contact (e.g., wound dressing) may be Class I or II.
- Local action vs. systemic effect – Devices with systemic absorption or metabolic interaction (e.g., drug-eluting stents) go to Class III.
- Energy source – Active devices powered by electricity or other energy (e.g., defibrillators) are generally Class II or III. Passive devices (e.g., orthopaedic screws) are often Class II.
These criteria are applied in a hierarchical manner. The NMPA also publishes a specific classification catalog (分类目录 fēnlèi mùlù) with over 4,000 entries. Foreign companies should first check if their device code is listed—if not, a classification determination application (分类界定申请 fēnlèi jièdìng shēnqǐng) is required, which can take 30–60 working days.
An additional nuance: China treats combination products (device + drug) differently. For example, a heparin-coated catheter is classified as Class III because the drug component introduces higher risk. Similarly, sterile products always require higher scrutiny even if the device itself appears low-risk.
3. Step-by-Step Decision Framework
Follow this six-step process to determine your device’s class in China.
- Identify your device code – Search the NMPA Classification Catalog using your product’s intended use, technical characteristics, and materials. Use the Chinese name or a translated description.
- Apply the classification rules – Score your device against the five factors above. If it is non-invasive, temporary, skin-only, passive, you are likely Class I. If invasive and short-term, Class II. If invasive, long-term, active, systemic, or contacting heart/CNS, Class III.
- Cross-check with similar devices – Look up competitors or reference devices already registered in China. Use the NMPA’s online database (https://www.nmpa.gov.cn) to see what class they hold.
- Request a classification determination (if needed) – For borderline devices, submit a classification application to the NMPA Medical Device Standardization Administration. Include device description, intended use, materials, and foreign classification.
- Engage a Chinese regulatory consultant – Verify your classification with an experienced RA (Regulatory Affairs) firm. China’s rules change frequently; a consultant can spot traps like “active device” definitions that differ from EU.
- Document your decision – Even if you proceed with a specific class, maintain a written rationale. NMPA auditors may ask why you classified as you did.
Note: Some foreign companies mistakenly assume that a device classified as Class I in the FDA is Class I in China. This is false. Example: a pulse oximeter is Class II in both the US and China, but a simple disposable thermometer is Class I in the US but may be Class II in China if it contains mercury or is electronic. Always check NMPA-specific rules.
Comparison Table: Class I vs. Class II vs. Class III Registration
| Parameter | Class I (Low Risk) | Class II (Medium Risk) | Class III (High Risk) |
|---|---|---|---|
| Regulatory Body | City-level NMPA | Provincial NMPA | National NMPA (Beijing) |
| Registration Type | Record filing (备案 bèi àn) | Registration approval (注册审批 zhùcè shěnpī) | Registration approval (注册审批 zhùcè shěnpī) |
| Clinical Trial Requirement | Not required | Usually a clinical evaluation report (CER); full trial may be waived for equivalent devices | Full clinical trial in China (≥ 100 subjects typical) |
| Average Timeline (submission to certificate) | 6–12 months | 12–24 months | 24–36 months |
| Estimated Total Cost (USD) | $5,000–15,000 | $20,000–60,000 | $80,000–300,000 |
| Validity Period | 5 years (renewal) | 5 years (renewal) | 5 years (renewal) |
| QMS Audit by NMPA | No (self-declaration) | Yes – on-site or remote audit | Yes – mandatory on-site audit for most devices |
| Example Devices | Bandages, cotton swabs | Infusion pump, blood glucose monitor | Coronary stent, ventilator |
Data sources: NMPA 2023 annual report, Medical Device Registration Fee Standard (2023 update), and industry averages from consulting firms. Actual costs vary by device complexity and consultant fees.
4. Common Pitfalls and How to Avoid Them
Even experienced regulatory teams can stumble. Here are three frequent mistakes:
- Assuming equivalence to USA/Europe – China has unique classification rules, especially for active devices and combination products. Always perform a stand-alone classification analysis.
- Overlooking sterile and reprocessed devices – In China, a non-invasive sterile wound dressing is still Class II because sterilization adds risk. Many companies falsely assume it is Class I.
- Ignoring the “two-licensing” requirement – Chinese regulations require both a device registration certificate (for the product) and a production license (for the manufacturing facility). Classification affects both. Class I devices do not need a production license, but Class II and III do.
To avoid these, always hire a local regulatory affairs partner with a track record of recent NMPA submissions. Relying on old classification documents (pre-2017) can lead to errors.
NEXT STEPS: Three Decision-Path Recommendations
If you are unsure about your device’s class, the safest step is to request a classification determination from the NMPA before investing in registration. This can be done through a CRO or consultant. Delaying classification can waste months and money.
